# Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene Substances in Schedule I > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/scheduling-novel-synthetic-opioids-schedule-i/ > **Published:** 2026-03-10T11:16:38-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:59:37-04:00 > **Clinical Summary:** Learn about the scheduling of novel synthetic opioids like butonitazene, flunitazene, and metodesnitazene in Schedule I and their clinical implications. --- ✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch  |  Regulations.gov PolicySafetyResearch Why This Matters This regulatory action scheduling three new synthetic opioids as Schedule I substances provides clinicians with clear legal guidance on substances that have no accepted medical use and high abuse potential, helping them recognize and avoid exposure to these emerging drugs in clinical settings. Understanding these scheduling updates is critical for healthcare providers to identify patients who may be using these novel synthetic opioids, as these substances present overdose risks comparable to other illicit opioids but may not be detected by standard drug screening or recognized by patients as dangerous alternatives to prescription medications. Clinical Summary The Drug Enforcement Administration has placed three novel synthetic opioids—butonitazene, flunitazene, and metodesnitazene—into Schedule I of the [Controlled Substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/) Act, recognizing their high abuse potential and lack of accepted medical use. These isotonitazene analogs have emerged as dangerous illicit drugs increasingly detected in overdose deaths and street drug supplies, particularly as fentanyl alternatives in illicit markets. While these specific substances are not cannabis-related, this scheduling action reflects the broader regulatory environment in which cannabinoid products operate, as the DEA continues to combat novel psychoactive substances that threaten [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/). For clinicians, this underscores the importance of screening patients for poly-substance use patterns, as individuals addicted to opioids may also use cannabis or cannabinoid products in self-management strategies. Clinicians should remain vigilant about emerging synthetic drugs in their communities and maintain updated knowledge of [controlled substance scheduling](https://cedclinic.com/marijuana-rescheduling-regulatory-updates-march-2026/) changes that may affect patient presentations and overdose risk assessments. Practitioners managing pain or [substance use disorders](https://cedclinic.com/cannabinoid-clinical-trials-mental-disorders-evidence-2/) should recognize that novel synthetic opioids now compete in illicit markets alongside cannabis products, necessitating comprehensive toxicology assessments and substance use counseling. Dr. Caplan’s Take “What we’re seeing with these synthetic opioids being emergency scheduled is exactly why I advocate for rescheduling cannabis at the federal level—we have decades of clinical data on [cannabis safety](https://cedclinic.com/respiratory-effects-inhalational-marijuana/) and efficacy, yet we classify it alongside drugs with no medical value, while we’re racing to ban novel synthetics we’ve barely studied. The DEA’s reactive approach to emerging drugs highlights a fundamental inconsistency in our drug policy that directly harms my patients who could benefit from cannabis but can’t access it legally or confidently.” Clinical Perspective The Drug Enforcement Administration’s scheduling of three novel nitazene opioids (butonitazene, flunitazene, and metodesnitazene) in Schedule I reflects the rapid emergence of synthetic opioids designed to circumvent existing regulations, a pattern clinicians should recognize as a persistent threat to overdose prevention efforts. These substances have demonstrated opioid receptor activity and have appeared in overdose cases, yet limited pharmacokinetic data and clinical experience exist to guide toxicology interpretation or treatment protocols in poisoned patients. The regulatory response appropriately prioritizes [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/), though the lag time between street emergence and formal scheduling—during which clinical and public health systems operate with incomplete information—remains a significant challenge for emergency departments and poison centers. Clinicians should maintain awareness that novel synthetic opioids continue to appear in illicit drug supplies, standard toxicology screens will not detect these agents, and supportive care plus nalox 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Schedules+of+Controlled+Substances%3A+Placement+of+Butonitazene%2C+Flunitazene%2C+and+Metodesnitazene+Subs...+%40drcaplan&url=https%3A%2F%2Fwww.regulations.gov%2Fdocument%2FDEA-2021-0031-0007) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.regulations.gov%2Fdocument%2FDEA-2021-0031-0007) [🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Schedules+of+Controlled+Substances%3A+Placement+of+Butonitazene%2C+Flunitazene%2C+and+Metodesnitazene+Subs...+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.regulations.gov%2Fdocument%2FDEA-2021-0031-0007) [📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/) [📝 Read more on Substack](https://substack.com/@doctorapproved) [🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [Daily Digest: Last 9 Hours: Stroke Risk From Recreational Drugs and DEA Scheduling Actions — March 08, 2026](https://cedclinic.com/daily-digest-last-9-hours-stroke-risk-from-recreational-drugs-and-dea-scheduling-actions-march-08-2026/) - [Firefighters are a step closer to being able to use medical cannabis – WMAR](https://cedclinic.com/medical-cannabis-firefighters-access-update/) - [Cannabis compounds CBD and CBG may help reverse fatty liver disease, study finds](https://cedclinic.com/cbd-cbg-fatty-liver-disease-research/) 📰 Source: [https://www.regulations.gov/document/DEA-2021-0031-0007](https://www.regulations.gov/document/DEA-2021-0031-0007) Further Reading Evidence Watch[`Cannabinoid Clinical Trials: CBD Cortical Excitability Study`](https://cedclinic.com/cannabidiol-lacks-intrinsic-anti-epileptic-properties-trial/) Research Digest[Daily Digest 2026-03-07](https://cedclinic.com/adolescent-cannabis-psychiatric-outcomes-2026-digest/) CED Clinic Blog[Cannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years](https://cedclinic.com/cannabis-beverage-substitution-alcohol-new-york-five-years/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Schedules of Controlled Substances: Placement of Etodesnitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I](https://cedclinic.com/schedules-controlled-substances-placement-schedule-i/) Explore the DEA's scheduling of additional synthetic opioids in Schedule I, highlighting emerging drug threats and regulatory responses. [Read More](https://cedclinic.com/schedules-controlled-substances-placement-schedule-i/) [Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I](https://cedclinic.com/mdmb-4en-pinaca-schedule-i-placement/) Detailed review of the scheduling of synthetic cannabinoids like MDMB-4en-PINACA and their implications for clinical practice. [Learn More](https://cedclinic.com/mdmb-4en-pinaca-schedule-i-placement/) [Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I](https://cedclinic.com/synthetic-cannabinoids-schedule-i-placement/) Comprehensive analysis of recent DEA scheduling actions on synthetic cannabinoids and their impact on public health. [Explore Now](https://cedclinic.com/synthetic-cannabinoids-schedule-i-placement/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).